An observational study in Rheumatoid Arthritis, Psoriatic Arthritis and Arthritis, sponsored by Vastra Gotaland Region. Enrolling by invitation at 1 site in Sweden. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-12.
Sponsored by Vastra Gotaland Region · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region — 2 open to participants now, 5 under way, none of them phase 3. Arthritis, Rheumatoid · Vastra Gotaland Region.
Among the 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region, this one is one of 3 that started in 2020, is one of 5 observational ones, and was the 7th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region are open now, in 1 country. Recruiting first, the newest first:
Vastra Gotaland Region · Sites in Sweden
Ages 18–85
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,100 is above the median of 176 across 1,017 observational studies indexed under Arthritis, Rheumatoid.
Median enrollment 81 across the 6 interventional studies, 2,500 across the 5 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vastra Gotaland Region is the lead sponsor of 276 studies on the registry; 110 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
GÖTHA- The early arthritis and psoriasis study of Region Västra Götaland, Sweden - is a longitudinal observational study, which will prospectively and in parallel follow patients with newly diagnosed rheumatoid arthritis (RA, N=1000), psoriatic arthritis (PsA, N=500) and undifferentiated arthritis (N=100), together with patients with psoriasis (N=500). The study will also recruit healthy controls from the general population (N=3000).
The aims of the study are to define predictors for disease course and severity, treatment response, comorbidities, health related quality of life (HRQoL) and health economy.
The study is a collaboration between the department of Rheumatology and the department of Dermatology at Sahlgrenska University Hospital in Gothenburg, and the departments of Rheumatology at the hospitals of Alingsås, Borås, Uddevalla and Skövde, in the west of Sweden.
All patients with newly diagnosed RA, PsA and undifferentiated arthritis at the Rheumatology centers are eligible for inclusion. Patients with psoriasis will be recruited from the Department of dermatology at Sahlgrenska University Hospital.
The patients will be examined at baseline and at one, three, five and ten years. The assessments will include physical examination with evaluation of joints, entheses and skin and validated questionnaires regarding medical history, comorbidities, lifestyle, disease activity, bodily function, socioeconomic factors and HRQoL. Blood samples will be collected. The patients with arthritis will also undergo radiography of the lung, hands and feet, and Cone Beam Computed Tomography (CBCT) of hands and feet.
All patients at any of the involved rheumatology clinics with newly diagnosed RA, PsA or undifferentiated arthritis meeting the study criteria are eligible for inclusion.
Consecutive sampling
Patients with psoriasis diagnosed at a dermatology clinic. Consecutive sampling
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with RA meeting the classification criteria of American College of Rheumatology (ACR) and/or European League Against Rheumatism (EULAR) från 2010.
Other: Care as usual
Patients with PsA meeting the classification criteria of Classification for Psoriatic Arthritis (CASPAR).
Other: Care as usual
Defined as a patients with a clear arthritis, but not meeting with established classifications criteria of any now known rheumatic disease.
Other: Care as usual
Patients with psoriasis diagnosed at a dermatology department. The patients should not have any history of joint complaints with a duration of more than 6 weeks.
Other: Care as usual
General population controls retrieved from the Population Register, matched for age, sex and residence of living to the included patients.
No intervention will be given. The study will follow the effects of care as usual.
Disease activity
Disease Activity Score using 28 joint counts (DAS28) score range 0-9.07
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2020 (actual). Primary completion is estimated for Dec 2039, 239 months after the start.
Of 235 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 239 months is above that.
Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.